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This study analyzes data from a select group of active duty (AD) service members 
enrolled to the Puget Sound area Navy military treatment facilities (MTF) in order to 
develop a model that identifies the risk that opioid users will become high opioid users, 
as defined by Navy Bureau of Medicine and Surgery (BUMED). The analysis examines 
the relationship between the response variable—high opioid user—as a function of a 
number of explanatory variables, including patient age, deployment history, sources of 
prescription and medical diagnoses.  Logistic regression and machine learning models are 
used for data analysis.   
The study concludes that a simple, executable model that consolidates the 
variables to two explanatory factors performs as well, if not better than, the more 
complicated machine learning models.  The two highly influential factors are the number 
of prescription sources for opioid medications and the total number of diagnoses.    
This logistic regression model has the potential to benefit Navy Medicine to make 
important decisions for their opioid-prescribed patients.  With the ability to identify the 
risk that an opioid user becomes a high user, healthcare leaders can better manage 
resources to focus on the prevention and treatment of higher-risk patients.  This 
concentrated coordination can result in improved patient care for this sub-population, 
reduced long-term cost for the military healthcare system and, overall, a more medically 
ready military force.      
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EXECUTIVE SUMMARY 
In an effort to build a model to identify the risk that opioid users may become 
high users, our study examines explanatory factors that influence opioid use.  The data is 
provided by the Analytics/Enterprise Support Services Department of BUMED and 
focuses on active duty (AD) service members enrolled to the Puget Sound area Navy 
military treatment facilities (MTF).  The analysis examines the relationship between the 
response variable, high opioid user, as a function of 91 explanatory variables, including 
patient age, deployment history, sources of prescription and medical diagnoses.  Basic 
logistic regression, elastic net penalized logistic regression, random forest and boosted 
tree classification models are used for our data analysis.   
We plotted cross-validated receiver operating characteristic (ROC) curves to 
compare model performance and to avoid over-fitting for the random forest and boosted 
tree models.  Although simpler, the basic logistic regression model performs well when 
compared to the complex machine learning models.  The logistic regression model is also 
easier to reproduce.  Just as importantly, the output is easy to understand and interpret.   
The log-odds and probability of a high user are a linear function of the two explanatory 
variables in the final logistic regression model and thus, conceptually, easier to 
communicate.   
Therefore, the recommended model for BUMED is a logistic regression model 
with two explanatory variables, without interactions.  These two variables, the number of 
prescription sources for opioid medications and the total number of diagnoses are 
constructed from the original data files from BUMED and encompass the majority of the 
91 explanatory variables.   
A lift curve is used for improved interpretability of the model for decision makers.  
The curve shows that with limited resources, if MTFs could subset the patients, by 
focusing on a percentage of the opioid user population with the highest estimated 
probability of high opioid use, the probability of identifying a high user can be improved 
by the amount of the lift.   
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This logistic regression model has the potential to benefit Navy Medicine to make 
important decisions for their opioid prescribed patients.  With the ability to identify the 
risk that an opioid user becomes a high user, health care leaders can better plan and 
manage finite resources to focus on the prevention and treatment of the higher risk 
patients.  This concentrated coordination of care can result in improved patient care for 
this sub-population, reduced long term cost for the military health care system and 
overall, a more operationally ready workforce.     
This research is an initial effort to explore ways to identify opioid users that may 
have greater risk of becoming a high opioid user.   For future studies, research can also 
examine data on patients that did not have opioids prescribed to compare the risk factors 
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In the United States, there is a growing epidemic that until recently has not 
received much media coverage: the use of opioids to relieve pain.  Opioids are a type of 
narcotic, commonly prescribed for pain.  Roughly 20% of patients with pain-related 
diagnoses are prescribed an opioid (Chou, Dowell, & Haegerich, 2016).  According to the 
National Institute on Drug Abuse (NIDA), opioids can be natural, semisynthetic or 
synthetic.  The drugs provide relief by reducing the intensity of pain signals to the brain 
and this, in turn, minimizes the effects of the painful stimulus (NIDA, 2014). Some 
common medications that are considered opioids include hydrocodone, oxycodone, 
morphine and codeine (NIDA, 2014).   
Opioid pain medications can present serious risks for the patient, including 
dependency, overdose and opioid-use disorder.  Opioid abuse has become the leading 
cause of preventable deaths in the United States (Rudd, Aleshire, Zibbell, & Gladden, 
2016).  In 2014 alone, according to the same source, there were over 47,000 deaths 
attributed to drug overdose and 61% of those deaths involved opioid overdoses. That is 
roughly 25% more deaths than from either firearms or motor vehicle accidents.  The 
Centers for Disease Control and Prevention (CDC) has historically characterized all 
opioid pain reliever deaths as prescription opioid overdoses (Rudd et al., 2016).  
Additionally, the numbers continue to dramatically increase; Figure 1, taken from a CDC 
(2015) report, shows that the rate of opioid overdoses has tripled since 2000.  This 
increase is alarming and present in all demographics, regardless of sex, age or race (Rudd 
et al., 2016).  The focus of this study is a specific population of opioid users, active duty 
(AD) military personnel.       
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Figure 1.  Overdose Death Rates from 2000–2014. Source: CDC (2015). 
A. BACKGROUND 
Several important factors contribute to the increase in opioid use and abuse.  The 
liberalization of laws governing the treatment of chronic pain, the aggressive marketing 
efforts of the pharmaceutical industry and the introduction of a different pain 
management standard that began in the 1990s have all played major roles.  Prior to 1990, 
U.S. physicians took a minimalist approach to treating chronic pain patients (Levy, 
Netzer, & Pikulin, 2014).   
In 2015, the CDC published suggested guidelines for prescribing opioids for 
chronic pain in the United States (Chou et al., 2016).  These guidelines specifically focus 
on affecting medical provider’s behavior to ensure the safest and most effective treatment 
for their patients.  The guidelines also discuss the use of opioids in treating chronic pain.  
The guidelines do not target treatment of patients with cancer, palliative care or end-of-
life type care.  Instead, they are intended for primary care providers, who treat chronic-
pain patients in outpatient settings, as they account for almost half of all opioid 
prescriptions.  Chou et al. (2016) noted that the recommendations are based on three key 
principles.  The first is that non-opioid therapy is the preferred method for chronic pain 
treatment.  The second is that the lowest possible opioid dosage should be selected to 
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reduce risk of overdose.  Thirdly, providers should always exercise caution when 
prescribing opioids while closely monitoring their patients. 
Opioid abuse is not just a problem for the civilian population.  It is a problem for 
our nation’s military personnel and veterans as well.  According to a Veterans Affairs 
(VA) study, veterans are twice as likely to die from accidental opioid overdose than non-
veterans (Childress, 2016).  Additionally, Childress (2016) noted, that more than half of 
veterans suffer from chronic pain, compared to only about 30% for the general 
population, where chronic pain is defined “as pain that lasts longer than three months or 
past the time of normal tissue healing.”  Until a few years ago, veterans with chronic pain 
were treated exclusively with opioids.  The prevention, assessment and treatment of 
chronic pain remain a tremendous challenge for health care providers (Childress, 2016).   
The Navy AD population is on average much younger than the general population.  
Nevertheless, in a recent Center for Naval Analyses (CNA) study of four large Navy 
military treatment facilities (MTF), roughly 25% to 32% of all AD beneficiaries received 
at least one opioid prescription during fiscal year (FY) 2013 (Levy et al., 2014).    
The United States Navy Bureau of Medicine and Surgery (BUMED) stresses in its 
vision statement “our health care is patient-centered and provides best value, preserves 
health, and maintains readiness” (Goff & Sayers, 2015).  Thus, two of BUMED’s three 
strategic principles are value and readiness.  More specifically, under the value principle, 
the goal is to decrease enrollee network cost by optimizing resource utilization and 
managing referrals in order to provide the best care at the best value.  Under the readiness 
principle, the goal is to deliver ready capabilities to the operational commander by 
aligning Navy Medicine’s “manning, training, and equipping to maintain a medically 
ready force (Goff & Sayers, 2015).” 
According to Levy et al. (2014), around 80% of health care resources for Navy 
beneficiaries are devoted to patients with chronic pain.  Since chronic pain patients are 
typically prescribed opioids, this group drives a disproportionate amount of the 
populations cost to the health care system.  Additionally, from an operational and 
readiness standpoint, the Navy may not be able to deploy patients who have been 
prescribed opioids for chronic pain or those that have many of the associated comorbid 
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conditions.  Thus, the need to identify and manage the high opioid user population is one 
of strategic importance that aligns with BUMED’s strategic principles of value and 
readiness.  
B. PURPOSE OF THE STUDY 
High opioid use is defined by the Navy and Marine Corps Public Health Center 
(NMCPHC) as having five or more prescriptions dispensed for select pain medications 
within 90 days (Broad, 2016).  Identifying a potential high opioid user early will allow 
health care professionals and leaders to more closely monitor this group of beneficiaries 
to ensure they receive comprehensive care while mitigating the cost and operational 
impact on the patient’s parent organization.  
This study examines over eighty demographic and patient medical variables for 
opioid users in an AD military population and builds a simple logistic regression model 
to estimate the probability an opioid user from this population is a high opioid user.  
While this model is not good for classifying a particular individual as a high opioid user, 
we show that it can be used to identify the increase in the concentration of high users in a 
smaller sub-population.  We also show that the simple model performs well or better than 
more complex machine learning models (penalized logistic regression, random forests, 
boosted trees) fit with the same data.  The results of this study can be used by BUMED to 
help achieve its strategic goals in the areas of readiness and value.    
C. ASSESSING AND DEFINING HIGH OPIOID USERS AMONG AD NAVY 
POPULATION 
Across different health care systems, multiple methodologies and definitions are 
used for patients treated for chronic pain.  In 2015, BUMED established a comprehensive 
case definition to assess and identify opioid-prescribed patients enrolled in Navy MTFs.  
The adopted definition for a high opioid user is the same as NMCPHC’s definition of five 
or more dispensing events of a medication likely to be associated with pain during the 
course of a 90-day period (Ellis, 2015).  The types of medication that would fall within 
this category are listed below to include certain therapeutic classes and selected 
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nonsteroidal anti-inflammatory drugs (NSAID) likely to be associated with pain 
(Ellis, 2015). 
 
 Opiate Agonists 
 Opiate Partial Agonists 
 Skeletal Muscle Relaxants 
 Centrally Acting Skeletal Muscle Relaxants 
 Direct-Acting Skeletal Muscle Relaxants 
 Gaba-derivative Skeletal Muscle Relaxants 
 Skeletal Muscle Relaxants, Misc. 
 Selected NSAIDS (Aspir, Celecoxib, Ketoro, Cambia, Rub, Sulindac) 
Based on those medications, BUMED extracted administrative medical data and 
the Pharmacy Detail Transaction Service (PDTS) data from the Military Health System 
Management Analysis and Reporting Tool (M2).  The data only includes AD service 
members with at least one opioid prescription in FY2014 or FY2015 who were enrolled 
to the Puget Sound area Naval MTF’s.  These are the five facilities:  
 Naval Hospital Bremerton 
 Naval Hospital Oak Harbor 
 Naval Branch Health Clinic Everett 
 Naval Branch Health Clinic Bangor 
 Naval Branch Health Clinic Puget Sound 
Patients diagnosed with any of the cancer-related codes were excluded from the 
high opioid user criteria and removed from the PDTS data.  Appendix A lists the codes 
associated with cancer diagnosis.  This group of patients are already closely monitored 
and specifically prescribed opioids for their cancer-induced pain.  Based on the pseudo-
identification (ID) code representing each member in the PDTS data, BUMED provided a 
risk data file that contained additional information about each particular patient.  The 
details of each field will be discussed in Chapter III.  Due to the Health Insurance 
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Portability and Accountability Act of 1996, that specifically deals with protected health 
information as well as personally identifiable information, much of the demographic 
information was removed from the data files.  There are a few limitations with this study.   
 Reporting errors due to improper or insufficient medical coding as well as 
data entry errors at the clinic may exist in M2 data.  Furthermore, care 
delivered in the operational setting may not be documented in this system.   
 The PDTS table includes data for all prescriptions dispensed by an MTF, 
civilian pharmacy, or mail order.  It cannot be determined if the patient 
was compliant with taking the medication as instructed.  
 Patients with cancer diagnoses that did not occur at the same time as their 
pain diagnosis could be included in this analysis.  
 Potential high opioid users that have changed enrollment sites during the 
FY2014 or FY2015 time period may not be detected as a high user.   
 Since the reporting period covers 24 months, patients that receive opioid 
prescriptions outside of this period will not be accounted for.    
D. THESIS ORGANIZATION 
Chapter II provides background information on high opioid users, chronic opioid 
users (COUs), and the connection between pain and opioids.  Chapter III provides 
descriptive statistics of variables used in the study and gives the details of data 
preparation.  Chapter IV explores the methodologies used, a description and assessment 
of the models and the results of the analysis.  The final chapter presents a summary of the 
study and offers recommendations for further analysis.   
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II. RELATED LITERATURE 
This chapter examines previous studies on patients identified as high and COUs.  
Additionally, we explore the relationships between a very specific patient group, the 
military population and opioid use.  By examining the common factors amongst this 
patient group, we hope to gain a better insight on possible predictors for AD sailors who 
may become high opioid users.    
A. HIGH OPIOID USERS 
According to the Institute of Medicine, pain is recognized as a significant public 
health problem in America with over 100 million people experiencing chronic pain (Levy 
et al., 2014).  The treatment of chronic pain is especially challenging for health care 
professionals.  Due to its complex condition, chronic pain can be defined in different 
ways.  According to the same source, chronic pain is defined as lasting for “greater than 
three months or past the time of normal tissue healing” and can result from previous 
medical conditions, injuries or unknown causes.  An analysis in 2012 by the National 
Health Interview Study showed that 11.2% of adults reported having daily pain (Chou et 
al., 2016).  In fact, Chou et al. noted that approximately one in three Americans will have 
chronic pain in their lifetime and over 80% of the chronic issues are on the neck or lower 
back.  This source also reported that the majority of patients who experience chronic pain 
are also diagnosed with depression. The belief is that the ongoing pain and disability 
leads to frustration and eventually takes a psychological toll (Chou et al., 2016).  
Additionally, chronic pain in some people resulted from a traumatic event that may also 
trigger post-traumatic stress disorder (PTSD) (“PTSD,” 2015).  The same source 
approximates that 15% to 35% of patients with chronic pain also have PTSD.  Only 2% 
of patients diagnosed with PTSD do not have chronic pain.  Thus, PTSD and chronic pain 
have a very clear connection (“PTSD,” 2015).    
Opioids are commonly prescribed for non-cancer pain symptoms.  There is 
always the risk of dependency, abuse and opioid use disorder, which is defined as a 
“pattern of opioid-use leading to clinically significant impairment” (Chou et al., 2016).  
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Thus, it is very important to identify and monitor patients who are considered high 
opioid users.   
The Navy and Marine Corps Public Health Center conducted an M2 data pull in 
2016 for each Navy MTF and discovered that roughly 4% of all AD Navy beneficiaries 
could be classified as high users (Broad, 2016).  The percentage may be a little higher 
overall, as about 2,200 people fitting the description of high users were excluded because 
the last enrollment record did not classify them as AD or Navy enrollees.  Table 1 lists 
each Navy MTF and its percentage of high opioid users. 
 High Users of Chronic Pain Medication among AD Navy 
Enrollees. Source: Broad (2016). 
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B. CHRONIC OPIOID USERS 
While there is evidence to support the short-term effectiveness of opioids in the 
reduction of pain, the evidence is not as clear for long-term use.  Very few studies have 
examined the effectiveness of opioids with outcomes beyond 12 months.  Yet, 
researchers estimated in 2005, that 3% to 4% of the U.S. adult population was prescribed 
long-term opioid therapy (Levy et al., 2014).  Levy also suggested that patients that have 
a history of opioid prescriptions have a greater risk for overdose and opioid use disorder.  
Thus, COUs, generally defined as patients who have been prescribed a 90-day or greater 
supply of opioids, are of particular interest to BUMED and health care professionals 
(Levy et al., 2014).   
In the CNA study of chronic opioid-use and lower-back pain among Navy 
beneficiaries at the four large Navy MTFs, they evaluated opioid-use in terms of episodes 
of use, days of supply and dosage (Levy et al., 2014).  Some of the important factors 
quantified included the following: 
 Was the patient also on anti-depressant? 
 Was an NSAID attempted to relieve the pain, before the onset of opioid 
therapy? 
 Did the patient receive drugs from other pharmacy sources in the civilian 
sector? 
Table 2 shows the percentage of AD opioid users and the percentage of AD COUs 
for each of the four large Navy MTFs.  A key point to note that is not depicted in the 
table is that, while the COU percentage amongst the AD population is low, ranging 
between 1.5% to 3%, the COUs among the retiree demographic ranged from 7.2% to 
13.6% of total opioid users for each facility.  This meant that age and military 
experiences are possibly highly influential factors.   
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 Percentage of Opioid Users and COUs for Each Facility. 
Source: Levy et al. (2014). 
 
 
CNA provided the following findings and recommendations relevant to this study 
(Levy et al., 2014).  
 AD personnel are less likely to become chronic users compared to 
dependents and retiree patients. 
 Users of anti-depressants are much more likely to be chronic users. 
 Those prescribed a NSAID such as ibuprofen or aspirin initially, before 
being prescribed opioid therapy, are less likely to be chronic users.  
 A higher percentage of COUs are chronic lower back pain patients versus 
patients with acute lower back pain.  
 Patients who receive prescriptions entirely in the direct care system or 
entirely in purchased care are less likely to be COUs than those who 
receive prescriptions in both systems.   
 11 
C. PTSD, PAIN AND OPIOIDS 
Based on recent research, there is a clear connection between chronic pain and 
PTSD.  The VA reported that 51% of patients with chronic lower back pain also had 
PTSD symptoms (“PTSD,” 2015).  In another study, over 50% of Iraq and Afghanistan 
veterans diagnosed with PTSD also received one or more chronic pain diagnoses 
(Seal, 2014).  Seal’s research suggested that there is evidence that chronic pain is more 
prevalent in female veterans who recently returned from combat.  Figure 2 compares the 
returning veterans from Iraq and Afghanistan that have pain diagnoses and examines 
whether they have no mental health diagnosis, with a mental health diagnosis (excluding 
PTSD) or have a PTSD diagnosis.  The red bars are larger depicting the prevalence of 
chronic pain in those diagnosed with PTSD.  
 
Figure 2.  PTSD and Chronic Pain. Source: Seal (2014). 
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There are several medical hypotheses for the link between PTSD and pain.  Seal 
presents a very compelling theory of mutual maintenance.  Because PTSD creates an 
anxiety state, the person’s pain perception is increased.  As the perception of pain is 
exacerbated, into possibly chronic pain, this leads to increased disability.  This, in turn, 
drives the person to perceive their pain to be even worse, which feeds back into the 
symptoms of PTSD.  Figure 3 illustrates this cycle.    
  
Figure 3.  The Mutual Maintenance Cycle. Source: Seal (2014). 
Thus, a logical follow-on is to examine the link between PTSD and opioid use.   
Seal’s presentation (2014) references research that shows patients with both pain and 
PTSD are more likely to be prescribed opioids than patients with pain but no PTSD 
diagnosis.  In her study of Iraq and Afghanistan veterans, she found that those with PTSD 
are over two and half times more likely to be prescribed opioids than those patients with 
no mental health diagnosis.  Additionally, Seal concluded that of the PTSD diagnosed 
veterans, those with severe PTSD symptoms are more likely to receive prescription 
opioids for their pain.  This conclusion places this group of patients into an even greater 
risk of adverse effects from opioid use.      
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III. DATA 
This chapter describes the data set analyzed in the study, the data preparation 
process and the description of the response and explanatory variables with some initial 
exploratory analysis.  The variables described in this chapter are used in Chapter IV to 
construct models to estimate the probability that an individual in the AD military sub-
population who has been prescribed an opioid at least once, is a high opioid user.   
The response variable, constructed from the data provided and described in this 
chapter is a binary variable indicating whether an individual is a high user of opioids or 
not a high user of opioids, but all individuals in the data studied have at least one 
prescription for opioids.     
There are 91 explanatory variables available directly from the data provided by 
BUMED.  They can be categorized into three types: 
 Eighty binary medical risk diagnoses (given in Appendix B) variables 
indicating whether the individual has or has not been diagnosed with the 
condition.   
 Five binary variables assigning prescription source as direct care, managed 
care support contractor, theater medical data store, TRICARE mail-order 
pharmacy and VA clinical/health data repository.    
 Six variables pertaining to the patient’s history that may have an influence 
on the patient’s opioid-use.    
The response and explanatory variables are discussed in greater detail in Section 
C of this chapter.  Additionally, a brief description and statistics on some of the 
explanatory variables is included in Section D.   
A. DATA SOURCE/CLEANING 
The data used for this study was obtained from BUMED Analytics/Enterprise 
Support Services Department.  The data contains information on AD patients assigned to 
Puget Sound area Naval MTF’s that received at least one opioid prescription in either 
FY2014 or FY2015.  The data was received in the form of two files, one for each fiscal 
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year.  Each file contains two spreadsheets, one with PDTS records and one containing the 
patient risk file.   
The PDTS spreadsheets have 7066 rows and 8066 rows for FY2014 and FY2015 
respectively.  Each row corresponds to a single opioid prescription issued in that year.  
The PDTS spreadsheets have three relevant fields: 
 Pseudo ID 
 Opioid issue date 
 Source of opioid 
Each patient is identified by their pseudo ID, assigned by BUMED to ensure 
patient confidentiality.  The response variable and the five binary variables assigning a 
prescription source are constructed from this file.   
The risk spreadsheets have 2889 rows for FY2014 and 3742 rows for FY2015.  
Each row corresponds to a patient who had at least one opioid prescription issued in that 
year.  There were 57 duplicate pseudo IDs for the FY2014 risk file and 48 duplicate 
pseudo IDs for the FY2015 risk file.  The files contain 86 fields for the explanatory 
variables (including the 80 medical diagnosis fields plus six others) and a field containing 
the ID.   
Each of the four spreadsheets are exported to comma separated value files and 
imported into the R programming environment for further manipulation (R Core 
Team, 2016).  The two PDTS files are combined before constructing the high user 
response variable based on BUMED’s definition.  Specifically, we define a high user to 
be any patient who is prescribed five or more opioids within 90 days based on the 
combined two-years of PDTS records.  From the combined PDTS files, we construct a 
single PDTS user output file with one row per unique pseudo ID and columns for pseudo 
ID, the minimum number of days between any sequence of five prescriptions for 
individuals with at least five prescriptions, and a column denoting whether the patient 
was a high user.  Figure 4 shows a histogram of the minimum number of days between a 
sequence of five opioid prescriptions, for each patient who has five or more prescriptions.  
The figure shows that only 649 patients have five or more prescriptions and only 235 
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patients, highlighted in red, have five or more prescriptions within a 90 day period 
accounting for 11.4% and 4.1% respectively, of the total patients in the data set.     
 
Figure 4.  A Histogram of the Minimum Number of Days between a Sequence of 
Five Opioid Prescriptions among Opioid Users with at Least Five 
Prescriptions in FY2014 and FY2015  
The two risk files are combined and then merged with the PDTS user output file 
based on pseudo IDs.  An additional column is added to annotate the fiscal year (FY2014 
or FY2015) of the source risk file.  The newly combined output file contains 6,631 
entries with some pseudo IDs appearing multiple times.  This file is then separated by 
fiscal year.  Duplicate ID’s within each fiscal year are merged, with the patient assuming 
the larger value for each explanatory variable.  For example, if the pseudo ID appeared 
three times in FY2014, with one entry having a risk score of one and another entry with a 
risk score of two and the third with a risk score of three, the updated file would contain 
the pseudo ID once, with a risk score value of three.  The higher value is adopted to 
assume a worse case patient characteristic.  This decreases the size of the FY2014 and 
FY2015 files to 2,831 and 3,692 patients respectively.     
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A summary of the number of high users and the total number of records for each 
fiscal year is provided in Table 3.  There is a larger proportion of high users in FY2014, 
0.063, than in FY2015, 0.041.  Treating the two years’ worth of Puget Sound data as 
samples from hypothetical FY2014 and FY2015 populations the large-sample test of the 
null hypothesis that the two years’ proportions are equal, is rejected with a p-value of 
0.0006.  We do not know why the proportions are different.  There may have been a 
change in how opioids are prescribed at the Puget Sound MTFs however there is no 
evidence of policy changes that may have affected these numbers.     
 Number of High Users for Each Fiscal Year 
Risk File Source Hi User Non-Hi User Total 
    FY2014     177     2654  2831 
    FY2015     153     3539  3692 
 
The two files, one for each fiscal year are re-combined into a single file.  To 
ensure that this final data set only has unique pseudo IDs, the same merging process is 
used.  For the 843 patients with records in the FY2014 and FY2015 risk files, the larger 
value of each explanatory variable is used, resulting in a data set with 5680 total patients.  
B. TRAINING AND TEST SETS 
We randomly split our data into training and test sets, with 75% for the training 
set and 25% for the test set.  The training set is used (in Chapter IV) to fit a number of 
different types of models, from which we will choose the “best.”  The test set is set aside 
until after the model fitting is complete and used to obtain unbiased estimates of 
measures of model performance.  Selection of the training and test sets is stratified by 
non-high and high users so that the same ratio of high users is found in both the training 
and the test set.  Table 4 summarizes the number of opioid users in the training and 
test sets.   
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 Number of High and Non-High Users in the Training and Test Sets 
  Training Set Test Set Total  
High User 176 59 235 
Non-High User 4083 1362 5445 
Total 4259 1421 5680 
 
C. RESPONSE AND EXPLANATORY VARIABLES 
The response variable used in the analysis for the models is binary: 1 indicating a 
high user of opioids and 0 if not.  The criteria for determining whether a patient is a high 
opioid user follows BUMED’s adopted definition of five or more dispensing events of a 
medication likely to be associated with pain during a 90-day period. This indicator 
response variable is generated from the PDTS and merged with the risk file according to 
the pseudo IDs.   
There are 88 variables eventually used in the analysis to fit the models.  The 
presence of medical risk conditions make up 77 of the variables.  Appendix B lists these 
medical risk conditions.  These conditions are selected directly from the M2 health risk 
conditions category file.  The risk conditions in M2 are based on the Wakely Risk 
Assessment (WRA) model that maps over 17,000 International Classification of Diseases 
(ICD) volume 9 diagnosis codes to 90 condition categories (Mehmud, 2012).  Appendix 
C lists the WRA condition categories.  BUMED selected 66 of the 90 condition 
categories that may be relevant to this study.  These are shown in Appendix C.  The M2 
medical conditions file contains 13 sub-categories not included in the WRA, that better 
reflect the military population’s common illnesses.  These are annotated in Appendix B 
and mostly pertain to mental health conditions like PTSD, neurotic disorders and 
disturbance of conduct.  Additionally, the following medical conditions were eliminated 
as possible factors to simplify our model because no patient in the data set possessed 
these diagnoses: 
 Cystic fibrosis 
 Disease of the blood (high) 
 Neoplasm cancer (very high) 
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The eleven variables describe patient characteristics as well as the five possible 
sources of a prescription.  The additional six patient characteristics include a categorical 
variable for age, presence of acute reaction to stress, a risk score, number of days since 
most recent Overseas Contingency Operation (OCO) deployment, a binary variable 
indicating if the individual was ever-deployed and a case management (CM) acuity level.  
Based on related studies, there are indications that some of these characteristics may 
affect a patient’s opioid usage (Seal, 2014).     
D. DESCRIPTIVE STATISTICS 
A brief description and basic statistics for the explanatory variables and their 
relationship to the response variable is in this section.  These include the patient 
characteristic variables, the five prescription source variables and a handful of medical 
risk diagnoses variables.  Because the exploratory analysis is part of the model fitting 
processes, the analysis in this section is based only on the 4259 entries of the training set.     
(1) Age Group Category 
Rather than give an age in years, the exploratory variable “Age Group Category,” 
taken directly from the M2 risk file, assigns a letter code, D–G, to patients whose ages 
are 18–24, 25–34, 35–44, 45–64, respectively.  Table 5 shows the number of high users 
for each age group.  Although Category E has the greatest number of opioid users, 
patients in Category G have the largest proportion of high users, thus the proportion of 
high users is increasing with age group.  Additionally, the data set contains 51 entries that 
did not have an assigned code. 
 Percentage of High Users by Age Group Categories 
Ages (Code Category) Hi User (%) Non-Hi User (%) Total 
18-24 (D) 31(2.7%) 1138 (97.3%) 1169 
25-34 (E) 65(3.7%) 1699 (96.3%) 1764 
35-44 (F) 56 (5.4%) 982 (94.6% 1038 
45-64 (G) 19 (8.0%) 218 (92.0%) 237 
No Assigned Code 5 (9.8%) 46 (90.2%) 51 
Total 176 (4.1%) 4083 (95.9%) 4259 
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(2) Acute Reaction to Stress 
The factor acute reaction to stress takes two values, “yes” and “no.”  This factor is 
defined as “a psychological condition arising in response to a terrifying or traumatic 
event” (Kenny, 2013).  These events can range from sexual assaults to extreme 
experiences from war conflicts.  As a result, military personnel can be at greater risk.  
Only nine entries were assigned this diagnosis as shown in Table 6.  Therefore, this factor 
will not likely influence our model.   
 Percentage of High Users by Acute Reaction to Stress  
Acute Reaction  Hi User (%) Non-Hi User (%) Total 
Yes 1 (11.1%) 8 (88.9%) 9 
No 175 (4.1%) 4075 (95.9%) 4250 
Total 176 (4.1%) 4083 (95.9%) 4259 
 
(3) Risk Score 
The risk score describes the person's expected relative cost in medical resources 
based on the diagnoses and drugs accumulated within the reporting period (DHA, 2016).  
The lower the score, the less risk for the patient.  A score of one means the individual is 
at normal risk.  This risk score is not truncated, so there is no upper bound.  In the 
training set, the score ranged from zero to forty seven.  Because only 186 patients have a 
risk score of five or greater, we assign these patients to a single category.  Table 7 lists 
the number and percentage of high users by risk score.  Figure 5 shows that as the risk 
increases, the proportion of high users of opioids also increases.  The red lines indicate 
the standard error bars for the proportion of high users in each risk score category.   
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 Percentage of High Users by Risk Score Category 
Risk Score Hi User (%) Non-Hi User (%) Total 
0 4 (0.4%) 1097(99.6%) 1101 
1 56 (2.9%) 1883 (97.1%) 1939 
2 38 (6.2%) 578 (93.8%) 616 
3 18(6.4%) 265 (93.6%) 283 
4 16 (11.9%) 118 (88.0%) 134 
5 or greater 44 (23.7%) 142 (76.3%) 186 
Total 176 (4.1%) 4083 (95.9%) 4259 
 
 
Figure 5.  Proportion of High Users in Each Risk Score Category 
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(4) Ever Deployed For OCO Deployment 
Studies such as Seal (2014) that links opioid use with deployments to Iraq and 
Afghanistan are not uncommon.  While the percentage of high users in Table 8 increases 
with an OCO deployment, it is only a 1.5% increase.   
 Percentage of High Users by Ever Deployed OCO  
Ever Deployed OCO Hi User (%) Non-Hi User (%) Total 
Yes 113 (4.8%) 2243 (95.2%) 2356 
No 63 (3.3%) 1840 (96.7%) 1903 
Total 176 (4.1%) 4083 (95.9%) 4259 
 
(5) CM Acuity Level 
Many patients do not have an assigned CM acuity level, because 91% of patients 
in the data set have not been assigned a case manager.  Case managers assign a score of 
one to five, with a higher score indicating a patient with more complex health issues, thus 
requiring greater medical oversight.  Appendix D explains the scoring in greater detail.  
The statistics in Table 9 indicate that there may be a relationship between acuity level and 
high opioid use as the p-value is 0.0682 based on Fisher’s Exact Test (McDonald, 2009). 
 Percentage of High Users by CM Acuity Level 
CM Acuity Level Hi User (%) Non-Hi User (%) Total 
0 129 (3.3%) 3766 (96.7%) 3895 
1 24 (11.1%) 192 (88.9%) 216 
2 13 (12.0%) 95 (88.0%) 108 
3 8 (25.8%) 23 (74.2%) 31 
4 0 (0.0%) 4 (1.0%) 4 
5 2 (40.0%) 3 (60%) 5 




(6) Source of Prescription 
There are five prescription source categories, each corresponding to a logical 
variable that takes value “TRUE” if at least one of the prescriptions for a particular 
patient comes from that source and value “FALSE” otherwise.  The five sources and their 
codes are:   
 D = Direct Care (includes VA mail order pharmacy refills made on behalf 
of participating MTFs) 
 M = Managed Care Support Contractor (MCSC) 
 R = Theater Medical Data Store 
 T = TRICARE’s Mail Order Program 
 V = VA CHDR (Clinical/Health Data Repository—Prescription drug 
information for dual MHS/VA eligible beneficiaries—fully funded by the 
VA) 
The statistics in Table 10 indicate that a majority of high opioid users received 
their prescriptions from direct care.  But a greater percentage of opioid users who receive 
their medication from the MCSC are high users.  Table 10 also shows that the number of 
high users from the other three sources is quite small.     
 Percentage of High Users by Source of Prescription  
Prescription Source Hi User (%) Non-Hi User (%) Total 
D 170 (4.4%) 3726 (95.6%) 3446 
M 87 (11.5%) 671 (88.5%) 758 
R 2 (3.1%) 62 (96.9%) 64 
T 0 (0.0%) 2 (1.0%) 2 





In the CNA study by Levy et al. (2014), it was noted that patients who received 
prescriptions from more than one source are more likely to become chronic users.  Table 
11 examines the relationship between number of source prescriptions and high opioid 
usage.  We also noted that out of the 84 high users that had two or more prescription 
sources, 82 of those used the direct and MCSC sources.  In our models we replace the 
five binary variables that indicate prescription source with a single variable, number of 
sources, that takes the value “1” if the number of sources is one and “2” otherwise. 
 Opioid Usage Based on Number of Prescription Sources 
Number of Sources Hi User (%) Non-Hi User (%) Total 
One 92 (2.4%) 3706 (97.6%) 3798 
Two or More 84 (18.2%) 377 (81.8%) 461 
Total 176 (4.1%) 4083 (95.9%) 4259 
 
(7) Medical Diagnoses 
Seal (2014) concluded that there is a link between pain, mental health disorders 
and PTSD with opioid use.  The following seven medical risk diagnoses are examined 
more closely in Table 12, since these diagnoses can be associated with pain or mental 
health disorders.    
 Anxiety Related Disorders 
 Dorsopathy 
 Fracture/Dislocation 
 Endocrine/Metabolic/Immunity Disorders (EMI) 





 Percentage of High Users by Diagnoses 
Diagnoses Hi User (%) Non-Hi User (%) Total 
(Y)Anxiety Disorders 38 (14.7%) 221 (85.3%) 259 
(N)Anxiety Disorders 138 (3.5%) 3862 (96.5%) 4000 
(Y)Dorsopathy High 41 (20.2%) 162 (79.8%) 203 
(N)Dorsopathy High 135 (3.3%) 3921 (96.7%) 4056 
(Y)Fracture/Dislocation 
Low 
50 (7.2%) 640 (92.8%) 690 
(N)Fracture/Dislocation 
Low 
126 (3.5%) 3443 (96.5%) 3569 
(Y)EMI Disorder Low 31 (8.7%) 324 (91.3%) 355 
(N) EMI Disorder Low 145 (3.7%) 3759 (96.3%) 3904 
(Y) BJMIN 79 (10.7%) 657 (89.3%) 736 
(N) BJMIN 97 (2.7%) 3426 (97.2%) 3523 
(Y)Arthopathy 80 (8.8%) 831 (91.2%) 911 
(N)Arthopathy 96 (2.9%) 3252 (97.1%) 3348 
(Y) PTSD 25 (18.1%) 113 (81.9%) 138 
(N) PTSD 151 (3.6%) 3970 (96.3%) 4121 
(Y)- Presence of condition 
(N)- Absence of condition 
 
Table 12 shows that for all of the above conditions, there is a percentage increase 
in the number of high users with the presence of the stated condition.  The percentage 
increase varies from 3.7% with the fracture/dislocation condition to 16.9% with the 
dorsopathy condition.  However some of these diagnoses may not have a significant 
impact in predicting high opioid use due to the low number of patients diagnosed with 
that condition.   
Additionally, since there are 77 medical risk conditions used in the analysis for 
the model, we explore whether the presence in the number of conditions is related to high 
opioid usage.  The red line in Figure 6 is a loess smoother (see Faraway (2015) for a 
description of loess smoothers) of the proportion of high users as a function of the 
number of diagnoses.  It depicts an increasing relationship in the proportion of high users 
as the number of diagnosis conditions increase.  The blue dots indicate the proportion of 
high users with exactly the number of diagnoses.  The gray dots in Figure 6 depict the 
binary response variable with random noise added to both the binary response variable 
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and the number of diagnoses to avoid overlap of points.  Because the relationship 
between the number of diagnoses and the proportion of high users is so strong, we also 
include this constructed variable, number of diagnoses in our modeling efforts.  
 
Figure 6.    Proportion of High Users by Number of Diagnoses   
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IV. ANALYSIS AND RESULTS    
The goal of this chapter is to produce a model to estimate the probability that an 
opioid-using individual is a high user based on the diagnoses and other variables 
provided by BUMED and discussed in Chapter III.  Estimated probabilities are not 
intended to be used to classify individuals as high users or not.  Instead, they give a score, 
much like a credit score, to aid health care decisions.  This chapter fits four models on the 
training data set and compares the results.  The four models are a basic logistic regression 
model and three machine learning models: the elastic net penalized logistic regression, 
the random forest and the boosted tree models.  The basic logistic regression model uses 
only a few explanatory variables selected from those described in Chapter III.  It has the 
advantage of being easy to use and to explain.  The machine learning models, on the 
other hand, make use of all the explanatory variables.  Our basic model is compared at 
the end of this chapter with the best model from the other three methods.  For those 
methods, we vary the parameters and choose the best model within each category type 
using cross-validated binomial deviance to avoid over-fitting (Hastie, Tibshirani, & 
Friedman, 2009).  We analyze the ROC curves based on the cross-validated predictors to 
choose the single best model among the three methods and then finally compare it with 
the basic model.  Plotting a lift curve on the test set will allow us to examine unbiased 
estimates of model performance for the best model for our study.    
A. BASIC MODEL 
For our basic high user model, our goal is to create a simple model based on 
variables that might have the strongest relationship to high opioid use.  The standard 
linear regression model is not appropriate in this study with a binary response variable.  
Instead, we use logistic regression, which is a generalization of linear regression for 
binary response variables (Faraway, 2015).  Logistic regression models are easily 
interpretable and are defined as follows: Let n be the number of observations in the 
training set and model the response variable as independent Bernoulli random variables 
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where the probability of a “high user,” Pi for i=1,…, n is related to the explanatory 
variables through the log-odds as shown in the following equation:    










    
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   ,                  
where Xi1,…Xik are the values of the k explanatory variables for the ith observation and β0, 
β1,…βk are the unknown parameters to be estimated.    
Based on Levy et al. (2014), patients who utilized multiple sources for their 
opioid prescriptions were found more likely to be a chronic user.  Further, based on our 
analysis in Chapter III, the number of diagnoses is strongly related to the proportion of 
high users.  This variable sums the 77 medical risk diagnoses indicator explanatory 
variables to produce a single variable.  Additionally, we consider the explanatory 
variables of risk score and CM acuity level in developing our basic model.  Two variables 
that we considered, but did not include in our basic model fit are the age group code and 
the number of days since most recent OCO deployment.  Neither variable improved the 
basic model fit. 
In Chapter III, we created two new explanatory variables: the total number of 
prescription sources and the total number of medical diagnoses for each opioid user.  We 
will begin with a model that includes both of these explanatory variables.  The fitted 
logistic regression model has the form: 
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where the P  is an estimated probability of high use for an individual, X1 is either one, 
representing one source of prescription or two, representing two or more sources of 
prescription respectively and X2 represents the total number of diagnoses.  The summary 
statistics for this logistic regression model fit are given in Table 13.  The z-values or 
Wald statistics and corresponding p-values are for a large sample test of the null 
hypothesis that each coefficient is zero against the two sided test alternative that it is 
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not (Hastie et al., 2009).  There is strong evidence that the coefficient for the number of 
sources is not zero and the same evidence is true for the other variable, number of 
diagnoses.  Thus, both explanatory variables should be used in our basic model.  The null 
and residual deviance for this model fit are 1466.2 on 4258 degrees of freedom and 
1184.3 on 4256 degrees of freedom.  The null deviance and the residual deviance are 
analogous to the total sum of squares and residual sums of squares for linear regression 
model fits and are often used to compute an R-squared value (Faraway, 2015).  Here the 
R-squared value is 0.24 with the interpretation that only 24% of the null deviance is 
explained by the logistic regression fit with two variables.   








(Intercept) -5.99 0.25 -23.50 <0.001 
Number of Sources 1.48 0.18 8.34 <0.001 
Number of 
Diagnoses 0.23 0.02 11.19 <0.001 
 
The values in Table 13 are on the scale of the log-odds of being a high user. 
Exponentiating the coefficients yields the odds ratios.  Subjects with multiple sources of 
prescriptions, have nearly 4.5 times the odds of being a high user than those with only 
one source (Odds Ratio (OR) = 4.4; 95% Confidence Interval (CI) (3.1-6.2)), holding the 
number of diagnoses constant.  Similarly, for every additional diagnosis, there is an 
increase in odds of being a high user (OR =1.26; 95% CI 1.21-1.31), holding the number 
of sources constant. 
To check that this is a reasonable basic model, we added the interaction between 
the two explanatory variables, the number of diagnoses and the number of source 
prescriptions.  The large-sample likelihood ratio test (LRT) of the null model without 
interaction against the alternative with interactions gives a p-value 0.037 with one degree 
of freedom.  There is evidence of interaction at a 5% level of significance, not at a 1% 
level.  With the large sample size, the model with interactions may be statistically 
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significant but may not be practically significant.  There needs to be performance 
improvement to choose a model with the interaction terms.  To see if there is a practical 
difference in the performance of the two model fits we compare their ROC curves.  
Common measures of performance used for models with a binary response variable are 
the true positive rate and false positive rate where an individual is classified as “positive” 
if the model estimated probability of positive is greater than a specified threshold (0.50 is 
a typical threshold value).  Here positive corresponds to high opioid use.  Rather than use 
a single threshold value, on the training data, the ROC curve considers both the true 
positive rate and the false positive rate for different threshold levels (James, Witten, 
Hastie, & Tibshirani, 2013).  In Figure 7, the ROC curve for the model with interactions 
is on top of the curve for the model without interactions.  Since the model without 
interactions is simpler and not notably improved when compared to the model with 
interactions, out of these two, we will choose the model without interactions.   
 
Figure 7.  ROC Curves Comparing Models with and without Interactions 
  
 31 
To check that the log-odds of high opioid use can be modeled as linear in the 
number of diagnoses, we converted the explanatory variable, number of diagnoses from 
numeric to categorical and compared the model fit with our current basic model.  The 
ROC curves for the two models plotted in Figure 8 look very similar, thus the simpler 
model, based on numeric rather than categorical version of the number of diagnoses 
variable remains our basic model.       
 
Figure 8.  Comparison of Models with Number of Diagnoses Converted to 
Categorical 
Additionally, we explored logistic regression with different combinations of the 
following four explanatory variables with and without interactions: number of 
prescription sources, number of diagnoses, risk score and CM acuity level.  Similar to the 
earlier results with using the ROC curve, when we compared each model with our basic 
model of two variables, our simple model had very similar, if not better results.  Thus, for 
practical purposes, our basic model will contain only two variables: the number of 
prescription sources and the number of diagnoses with no interactions.     
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B. MACHINE LEARNING MODELS 
In this section, we compare the three machine learning models:  elastic net 
penalized logistic regression, random forest and boosted trees.  For each method, we vary 
the parameters and use cross-validated binomial deviance to choose the best model within 
each category type.  In order to choose the single best machine learning model, we 
analyze ROC curves based on cross-validated true positive and false positive rates.  
1. Elastic Net Penalized Logistic Regression Model 
We use a function called cv.glmnet to conduct 10-fold cross-validation. This 
function is part of the glmnet package in R (Friedman, Hastie, & Tibshirani, 2010) that 
fits a regularized generalized linear model via penalized maximum likelihood.  In these 
models, penalties are functions of the magnitudes of the explanatory variables’ 
coefficients.  The three choices of penalties are the least absolute shrinkage and selection 
operator (lasso), L1 absolute value penalty, the ridge regression, L2 quadratic penalty or a 
combination of the two called the elastic net (Goeman, 2010).  How much the likelihood 
is penalized is governed by a parameter , chosen by cross-validation.   
Tibshirani (1996), suggests that an L1 lasso penalty performs better than the ridge 
penalty when there are a small to moderate number of moderate-sized effects, even out of 
a large number of explanatory variables.  An L2 ridge penalty performs best when there 
are large number of small effects such as when there is much multi-collinearity among 
the explanatory variables.  The advantage of the lasso penalty is that it acts as a variable 
selection procedure by shrinking coefficients to zero.  A shortcoming for lasso is when a 
group of variables are highly correlated, it tends to select only one variable from 
that group.   
To use the glmnet package, all explanatory variables must be numeric.  We 
converted three categorical variables, CM acuity level, risk score and age group code, to 
numeric variables.  CM acuity levels were consolidated to form a new binary variable, 
where a “1” represents an individual assigned an acuity level and “0” meant patient was 
not assigned an acuity level.  The age group code variable was converted from 
categorical with levels “D,” “E,” “F,” “G” to numeric with values 1, 2, 3 and 4 
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respectively.  Lastly, the risk score, with levels 0, 1, 2, 3, 4, 5+ was converted to a 
numeric variable with values 1 to 6.      
To choose the parameter , we compute the cross-validated prediction error for 
approximately 100 different values of .  For cross-validation, we use K=10 randomly-
selected folds.  The cv.glmnet function fits the model to nine folds and then predicts on 
the remaining fold.  This process yields a prediction error, CV1 and is repeated K-1 times 
yielding the corresponding K-1 prediction errors.  The average of the ten prediction errors 
results in CV, the cross-validated prediction error in the following equation (Hastie et 










We use the Bernoulli (or binomial) deviance as a measure of prediction error.  
The plot in Figure 9 shows the cross-validated prediction error for the lasso logistic 
model as a function of log( ).  The left most dotted vertical line shows the  associated 
with the minimum cross-validated prediction error.  The dotted line to the right shows the 
smallest   within the one standard error (SE) of the minimum cross-validated error.  This 
“one-SE rule”   tends to give a simpler model.  The numbers across the top are the 
corresponding number of variables with non-zero coefficients for that cross-validated 




Figure 9.  Cross-Validation Error vs. Log( ) for Binomial GLM 
We also penalized the logistic regression models with elastic net penalty.  Here 
the penalty is a combination of lasso and ridge penalties with parameter  , where  =1 
is a lasso penalty,  = 0 is a ridge penalty and 0< <1 is a combination of the two.  We 
fit elastic net models varying  from zero to one in increments of 0.1.  For each  , the 
one-SE rule  , yielded a cross-validated prediction error given in Table 14.  The 
smallest of these is for  = 1 corresponding to a lasso penalty.  Thus our best model 
among the penalized logistic regression models, chosen among models using all possible 
explanatory variables, is the model with three explanatory variables: the two variables in 
the basic model and the medical diagnosis dorsopathies high.   
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 Lowest CV while Varying  .  













2. Tree-Based Models 
We fit two machine learning models based on Breiman’s (2001) classification 
trees.  See James et al. (2013) for a good discussion of classification trees and related 
models.  For our modeling purposes, the greatest advantage of tree-based models is that 
they naturally accommodate potential interactions among explanatory variables.  In 
contrast, for logistic regression type models, interactions must be deliberately included as 
extra explanatory variables.  The two tree-based models considered in this section are 
random forests and boosted trees.   
a. Random Forest 
Random forests average the outcomes of multiple classification trees (Breiman, 
2001).  Each tree is fit using a bootstrapped sample taken from the training set and during 
tree construction only “mtry” number of variables randomly selected from the set of 
explanatory variables are considered at each split (where mtry is a parameter selected by 
the user).  We use the randomForest package to fit an initial model, while varying the 
value of mtry, the number of variables randomly sampled at each split (Liaw & 
Wiener, 2002).  The default value of mtry is the square root of the number of 
explanatory variables.    
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This method also produces variable importance measures by averaging the 
outcomes of the trees.  These variable importances explain variation in the response as a 
function of the explanatory variables.  Variable importance provides the average 
importance of each variable within the model based on the mean decrease in node 
impurity or gini score (Breiman, 2001).  Table 15 lists the most influential explanatory 
variables in the final random forest model based on gini score.  The larger the value, the 
greater the role that explanatory variable plays in partitioning the data (Witten, Frank, & 
Hall, 2011).  All five of these variables were explored while constructing our basic 
logistic regression model in Section A.   
 Top Five Influential Variables 
Explanatory Variable Mean Decrease Gini 
Number of Diagnoses     23.9215071 
Days Since Most Recent OCO Depl   23.01504065 
Risk Score  17.51883699 
Age Group Code 15.07520383 
Number of Sources     13.25949064 
 
In addition, we use the train function from the caret package in R to automate 
searching for the best mtry (Kuhn, 2016). This function returns an object that contains the 
performance values for each combination of model parameters specified.  We use the ten-
fold cross-validation to find the model with the lowest cross-validated log-loss (which is 
proportional to the Bernoulli deviance).  Figure 10 suggests that the minimum cross-
validated log-loss value occurs between ten to 16 randomly selected 
explanatory variables.  
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Figure 10.  Cross-Validated Log-Loss Based on Number of Variables 
We select 14 as our mtry value because it has the smallest cross-validated log-loss 
according to Table 16.  Our random forest model needs to have a sufficient number of 
trees to ensure every input row gets predicted at least a few times to give good 
performance and that the classification error stabilizes (James et al., 2013).  For this 
reason, our best random forest model grows 500 trees and randomly selects 14 
explanatory variables at each split.    
 Log-Loss for Various Mtry Values  














b. Boosted Tree 
Like a random forest model, the boosted tree model is another tree-based model 
that is a linear function of classification trees.  However, it grows incrementally to 
improve the prediction results (James et al., 2013).  This is different from random forest 
as the growth of a particular tree is influenced by the performance of those that have 
already been grown.  Thus, the trees may not need to be as large and this helps with 
interpretability.  The maximum tree depth corresponds to the potential degree of 
interaction among explanatory variables.  For example, trees with a single split (depth 
one) are additive with no interactions, trees with depth two can include up to two-way 
interactions, etc.  The trees improve by fitting to the previous residuals instead of to a 
response variable and continues until a specified number of trees are created (James et 
al., 2013).   
The tuning parameters for boosted tree models are the number of trees, the 
shrinkage or learning rate, and the interaction depth.  We use cross-validation to select an 
appropriate number of trees as overfitting can occur if this parameter is too large.  For the 
shrinkage parameter, we used a recommended starting value of 0.001 according to 
James et al. (2013).  We varied this parameter up to 0.05 to find combinations of 
shrinkage parameter and number of trees that could achieve good performance.  The third 
parameter, interaction depth, controls the degree of interaction and adds complexity to the 
model.  For example, an interaction depth of 2 gives a model with up to two-way 
interactions.   e varied this parameter from 1 to 4 and using cross-validation found that 
complex interactions were not needed.    
 We use the gbm function in R from the GBM package to construct our boosted 
decision tree (Ridgeway, 2015).  To choose the optimal model, we use ten-fold cross-
validation on the Bernoulli deviance.  The three parameters in this model that have the 
smallest cross-validated Bernoulli deviance are 244 trees, 0.05 shrinkage rate and an 
interaction depth of two.  This model fit suggests that including two-way interactions 
among the explanatory variables might improve model performance.   
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C. COMPARISON OF MODELS BUILT FROM MACHINE LEARNING 
APPROACHES  
ROC curves are used to compare the performance of the three machine learning 
models in our study:  lasso penalized logistic regression, random forests and boosted 
trees.  It appears initially that the random forest and boosted tree models outperformed 
the lasso penalized regression when analyzing the ROC curves on the training data.   
Upon further examination, the two tree-based models had over-fit the training data and 
thus had inflated model performance.  Figure 11 shows the random forest ROC curve 
based on the training set.  It indicates that the random forest model can predict high 
opioid use with almost 100% accuracy on the training set.  Unfortunately, these results do 
not generalize to an independent data set.  Therefore, to compare our machine learning 
models, we plot the cross-validated ROC curves.   
 
Figure 11.  ROC Plot of Over-Fit Random Forest Model on Training Set 
Based on Figure 12, the lasso penalized logistic regression and the boosted tree 
performed similarly well on the cross-validated ROC curve and slightly better than the 
random forest model.  However, because the boosted model uses many trees and all of 
the explanatory variables, it is comparatively more complex than the lasso penalized 
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regression.  For this reason, our choice for the best machine learning model is the lasso 
penalized regression.  The evaluation of the cross-validated ROC curve performance and 
model simplicity will be our approach in comparing our best machine learning model 
with the basic logistic regression model.   
 
Figure 12.  Cross-Validated ROC Curves Comparing Machine Learning Models 
D. RESULTS AND DISCUSSION 
In this section, we compare the lasso penalized logistic model with our basic 
logistic regression model.  Figure 13 displays the performance of the two models using 
their cross-validated ROC curves.  There is little difference in ROC curve performance 
between the two models.  So applying the simplistic approach to model selection, the 
model we recommend for implementation in a health care setting is the simpler logistic 
regression model.  There are a few reasons for this.  First and foremost, is easier 
implementation.  A logistic regression with two explanatory factors and with one fewer 
explanatory variable is easy to replicate and reproduce.  The log-odds and probability of a 
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high user for the logistic regression model are explicit and thus, conceptually, easy to 
communicate.   
 
Figure 13.  Cross-Validated ROC Curves Comparing Basic Logistic Model with 
Boosted Tree Regression Model  
With the selection of our basic logistic regression model as the preferred model 
for implementation, we evaluate its performance on the test set and using a more practical 
approach to evaluate model performance by plotting a lift curve.  This is a more 
functional method to examine how our model performs.  Think of the estimated 
probability of high opioid use (or equivalently, the estimated log-odds) as an individual’s 
score.  Now suppose we compute this score for all opioid users in a population, ranking 
their scores from highest to lowest.  If the model is useful the sub-population with the 
highest scores should have a larger proportion of high opioid users than the proportion of 
high opioid users in the entire population.  Lift is defined as the ratio of the proportion of 
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high users in the sub-population to the ratio of high users in the general population.  The 
lift plot gives lift as a function of the proportion in the sub-population.  Lift curves 
always reach point (1,1) because by dedicating resources to 100% of the population, the 
probability of identifying a high user will be the same as the actual probability of high 
users in the data set (Witten et al., 2011).    
Figure 14 shows the lift curve on the test set to analyze model performance.  Due 
to the low number of high users in the test data set, the logistic regression had a lot of 
variation when the proportion of the total population is less than 0.05.  The lift curve goes 
through the x coordinate at 0.10 and intersects the y coordinate at four, meaning there is a 
lift of four.  In practical terms, by dedicating resources to only 10% of the population, we 
can now improve and correctly assess the proportion of high users at four times the actual 
rate.  Since the actual percentage of high users in our test set is 4%, we improve our 
probability of identifying a high user to 16%.  Likewise, if we dedicate resources to 50% 
of the population, the lift is two, meaning the probability of identifying a high user is 
doubled.  So depending on how well we want to assess the proportion of high users or 
how much resources we have available for use, we can vary the certain threshold sub-
population to increase our probability of identifying a high user.   
We should note that the lift plot in Figure 14 only shows as an estimate of model 
performance.  However, it illustrates how a model like the basic model might be useful in 
practice.  In the next chapter we outline how our modeling efforts can be improved to be 
used as an operational health care tool.   
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Figure 14.  Lift Curve of the Basic Logistic Regression Model on the Test Set 
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V. CONCLUSIONS AND RECOMMENDATIONS  
Our goal for this thesis is to examine opioid users in the AD military population 
and to build a model that estimates the probability that an opioid-using individual is a 
high user as defined by BUMED.  In order to build a good performing model, we had to 
examine many explanatory variables that potentially influence an individual’s opioid use.  
Our approach was to select, if possible, a simple, executable model and as a result, we 
reduced the initial 91 variables down to two.   
The model that we recommend is a logistic regression model with two 
explanatory variables, with no interactions.  Those two variables are the number of 
prescription sources for the opioid medications and the total number of diagnoses from 
the M2 risk file.  Although simpler, this model performed well when compared to the 
more complex machine learning models.   
This logistic regression model has the potential to benefit Navy Medicine to make 
important decisions for their opioid prescribed patients.  The tool estimates the 
probability that an opioid user is a high user.  With this information, health care leaders 
can better plan and manage finite resources to focus on the prevention and treatment of 
the higher risk patients.  This concentrated coordination of care results in improved 
patient care for this sub-population, reduced long term cost for the military health care 
system and overall, a more medically ready military force.   
Due to the limited demographics data (for example, gender is not included among 
our explanatory variables) and time period of the data set, spanning only two years, there 
are factors associated with high opioid users that may not be accounted for.  Additionally, 
the nature of military jobs involves changing duty stations and MTF assignments every 
few years.  The fact that we are only observing AD assigned to the Puget Sound area 
clinics means that high opioid users that change enrollment sites away from those clinics 
are under-represented.  It also means that AD assigned to Puget Sound might not 
represent a cross-section of the general Navy population.  Lastly, the study analyzed AD 
patients who were already prescribed opioids to examine factors that can contribute to 
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high opioid use.  This excludes data for analysis of the majority of the AD patients who 
were not prescribed opioids.   
For this reason, a suitable follow-on study could examine data on patients that did 
not have opioids prescribed to compare the risk factors of becoming an opioid user.  The 
follow-on study should also consider a number of other explanatory variables such as 
gender and type of duty and be expanded to include other MTFs.  Further, if complete 
records of opioid prescription use are not available because patients change duty stations, 
then dates a patient enrolls and dis-enrolls from the MTF must be included.  With that 
said, this research is simply an initial effort to explore ways to identify opioid prescribed 




APPENDIX A.  CANCER DIAGNOSIS CODES 











THIS PAGE INTENTIONALLY LEFT BLANK 
 51 






















































Neoplasm.Cancer..Med.   
* Denotes variables added that are not part of the M2 medical risk conditions. 
++ Denotes variables not in the WRA model. 
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APPENDIX C.  MEDICAL CONDITION CATEGORIES IN WRA 
MODEL 
The following table lists the 90 condition categories in the Wakely Risk Assessment 
Model (Mehmud, 2012). 
 
WRA Category Description WRA# 
Arthropathies WRA1 
Bone/Joint/Muscle Infections/Necrosis WRA2 
Central Nervous System WRA3 
Central Nervous System (H) WRA4 
Cerebral Palsy, Hemorrhage and Other Paralytic Syndromes WRA5 
Cerebrovascular Disease WRA6 
Chronic Ulcer of Skin, Except Decubitus WRA7 
Circulatory/Cardiovascular (H) WRA8 
Circulatory/Cardiovascular (L) WRA9 
Circulatory/Cardiovascular (M) WRA10 
Cirrhosis of Liver* WRA11 
Congestive Heart Failure WRA12 
Cystic Fibrosis WRA13 
Diabetes with Ophthalmologic or Unspecified Manifestation WRA14 
Diabetes with Renal or Other Specified Manifestation WRA15 
Diabetes without Complication WRA16 
Dialysis Status* WRA17 
Diseases of the Blood (H) WRA18 
Diseases of the Blood (L) WRA19 
Diseases of the Blood (M) WRA20 
Diseases of the Blood (VH) WRA21 
Diseases of the Ear/Mastoid Process WRA22 
Diseases of the Genitourinary System WRA23 
Disorders of Immunity WRA24 
Disorders of the Eye & Adnexa WRA25 
Dorsopathies WRA26 
Dorsopathies (H) WRA27 
Drug/Alcohol Psychosis or Dependence WRA28 
Endocrine, Metabolic, and Immunity Disorders WRA29 
Endocrine, Metabolic, and Immunity Disorders (H) WRA30 
End-Stage Liver Disease* WRA31 
EXCL* WRA32 
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WRA Category Description WRA# 
Fracture/Dislocation WRA33 
Gastrointestinal/Infectious/Parasitic (H) WRA34 
Gastrointestinal/Infectious/Parasitic (L) WRA35 
Gastrointestinal/Infectious/Parasitic (M) WRA36 
HIV/AIDS* WRA37 
Inflammatory Bowel Disease* WRA38 
Injury/Poisoning WRA39 
Lymphatic, Head and Neck, Brain, and Other Major Cancers (H)* WRA40 
Lymphatic, Head and Neck, Brain, and Other Major Cancers (L)* WRA41 
Lymphatic, Head and Neck, Brain, and Other Major Cancers 
(M)* 
WRA42 
Major Complications of Medical Care and Trauma WRA43 
Major Depressive, Bipolar, and Paranoid Disorders WRA44 
Major Organ Transplant Status* WRA45 
Mental Disorders WRA46 
Mental Disorders (H) WRA47 
Metastatic Cancer and Acute Leukemia* WRA48 
Multiple Sclerosis WRA49 
Neonate* WRA50 
Neonate (H)* WRA51 
Neoplasm of Bone, Connective Tissue, Skin, & Breast WRA52 
Neoplasm of Bone, Connective Tissue, Skin, & Breast (H) WRA53 
Neoplasm of Digestive/Peritoneum WRA54 
Nephritis* WRA55 
Osteoarthrosis WRA56 
Other Congenital Anomalies WRA57 
Other Digestive System Diseases WRA58 
Other Heart Disease WRA59 
Other Infectious & Parasitic Diseases* WRA60 
Other Infectious & Parasitic Diseases (H)* WRA61 
Other Musculoskeletal System & Connective Tissue WRA62 
Other Mycoses WRA63 
Other Neoplasm WRA64 
Other Pulmonary/Respiratory WRA65 
Other Rare* WRA66 
Other Transplant Related* WRA67 
Parkinson's and Huntington's, other motor control Diseases* WRA68 
Polyneuropathy WRA69 
Pregnancy (Incomplete)* WRA70 
Pregnancy Related* WRA71 
Proliferative Diabetic Retinopathy and Vitreous Hemorrhage* WRA72 
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WRA Category Description WRA# 
Protein-Calorie Malnutrition* WRA73 
Pulmonary/Respiratory (H) WRA74 
Pulmonary/Respiratory (L) WRA75 
Pulmonary/Respiratory (M) WRA76 
Quadriplegia, Other Extensive Paralysis WRA77 
Renal Failure (H) WRA78 
Renal Failure (L) WRA79 
Renal Failure (M) WRA80 
Respirator Arrest, Dependence/Tracheostomy Status WRA81 




Seizure Disorders and Convulsions WRA84 
Septicemia/Shock WRA85 
Skin & Subcutaneous Tissue WRA86 
Skin & Subcutaneous Tissue (H) WRA87 
Vascular Disease WRA88 
Vertebral Fractures, Spinal Cord Diseases/Injury WRA89 
Very Severe Neoplasm / Cancer WRA90 
*Denotes medical conditions that were not included in this study. 
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APPENDIX D. CASE MANAGEMENT (CM) ACUITY LEVELS 
The information in the following table defines the CM acuity level (DHA, 2016). 
 
1 Low 1-150 minutes per month 
or (0-2.5 hrs per month 
Routine discharge planning, 
minimal intervention(s).   
2 Low to 
moderate 
151-360 minutes per 
month or (2.75 - 6.00 
hours per month 
Stable with ongoing needs, 
chronic care intervention, 
infrequent ER/inpatient utilization  
3 Moderate 361-555 minutes per 
month or (6.25 - 9.25 
hours per month) 
Stable with more complicated 
ongoing needs, frequent 
ER/inpatient utilization 
4 Moderate to 
Intense 
556-750 minutes per 
month or (0.5 - 12.5 hrs 
per month) 
Multiple acute needs  
5 Intense 751 minutes and above 
per month (12.75+ hrs per 
month) 
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